###begin article-title 0
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Age-dependent penetrance of different germline mutations in the BRCA1 gene
###end article-title 0
###begin p 1
black triangle right Additional data are published online only at
###end p 1
###begin p 2
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin title 3
Aims:
###end title 3
###begin p 4
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
BRCA1 gene mutations have been extensively studied in relation to breast and ovarian cancer susceptibility. Various genotype-phenotype correlation attempts have yielded important data pertaining to the consequences of BRCA1 mutations. However, little is known about the effects of recurrent BRCA mutations on expressivity and the age of onset of cancer in a population. This study addresses whether different exon mutations have variable expressivity especially in relation to the age of onset of breast cancer.
###end p 4
###begin title 5
Methods:
###end title 5
###begin p 6
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Using a step-wise systematic approach, culminating in the sequencing of all BRCA1 and BRCA2 exons with the addition of multiplex ligation-dependent probe amplification, the relationship between disease phenotypes and gene mutations in 219 individuals and their family members was examined.
###end p 6
###begin title 7
Results:
###end title 7
###begin p 8
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 517 522 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 571 576 571 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
It is shown that different BRCA1 gene mutations have distinct effects that influence the age of onset of breast or ovarian cancer. Mutations in exon 2 of the BRCA1 gene had significantly lower penetrance compared with mutations of exons 11, 13 and 20. The median age of affliction with breast cancer was 55 years for 185delAG in exon 2 (95% confidence interval (CI) 46.7 to 59.5), 47 years for the 4184delTCAA mutation in exon 11 (95% CI 39 to 55.4), and 41 years for exon 13 duplication (95% CI 32.9 to 49.7) of the BRCA1 gene. Moreover, 14 novel mutations in BRCA1 and BRCA2 genes in the Yorkshire/Humberside population were identified.
###end p 8
###begin p 9
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Conclusions: The 185delAG mutation of the BRCA1 gene is a low penetrance mutation that is age dependent especially when compared with the exon 13 duplication mutation. The data have important ramifications on screening, genetic counselling and prophylactic treatment of BRCA1 gene mutation carriers.
###end p 9
###begin p 10
###xml 56 57 56 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 219 220 219 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 368 373 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 392 397 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 411 412 411 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 627 632 627 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 865 866 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 931 936 931 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 941 946 941 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 1122 1123 1122 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 50 55 <span type="species:ncbi:9606">women</span>
###xml 474 479 <span type="species:ncbi:9606">Women</span>
Breast cancer is the most prevalent malignancy in women.1 In the western hemisphere the lifetime risk of developing breast cancer is more than 10%. Ovarian cancer, on the other hand accounts for a lifetime risk of 1.8%.2 The majority of breast and ovarian cancers are sporadic or not inherited. Germline mutations in the breast and ovarian cancer susceptibility genes BRCA1 (MIM 113705)3 and BRCA2 (MIM 600185)45 confer a high risk of developing breast and ovarian cancers. Women with a mutation in the BRCA1 gene have a lifetime risk of 80-90% of developing breast cancer, and 40-65% chance of developing ovarian cancer.6 For BRCA2 gene mutation carriers, the estimated cumulative risk of breast cancer has been shown to be 28% by age 50 years, and 84% by age 70 years.7 The risk of ovarian cancer has been shown to be 0.4% by age 50 years and 27% by age 70 years.7 Nevertheless, the magnitude of risk to carriers of the germline BRCA1 and BRCA2 remains controversial2 and the controversy could partly have stemmed from the use of different populations and study designs, and the lack of specific mutation stratification.8
###end p 10
###begin p 11
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 507 512 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 666 671 666 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 798 799 798 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;</sup>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 855 860 855 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 891 896 891 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 1030 1032 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 1228 1233 1228 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1237 1242 1237 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1331 1336 1331 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1340 1345 1340 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1516 1521 1516 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1795 1800 1795 1800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1805 1810 1805 1810 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
The Breast Cancer Information Core Database (BIC) lists more than 1560 and 1880 mutations and polymorphisms in the BRCA1 and BRCA2 genes respectively. The influences of each mutation type (genotype) on expressivity, cancer type and age-dependent penetrance (phenotype) remain either controversial or unexplored. In the last decade, several reports have been published supporting the hypothesis that different mutations in the BRCA1 or BRCA2 genes confer different cancer-related risks. For example, Gayther et al (1995) reported that the risk of ovarian cancer relative to the risk of breast cancer was higher in families with mutations located 5' to exon 13 of the BRCA1 gene compared with families with mutations located 3' to exon 13.9 However, this finding was not confirmed in later reports.10-12 Also, an ovarian cancer cluster region (OCCR) in the BRCA2 gene was described by Gayther et al (1997).13 A later international collaborative study provided no statistically significant support for the existence of such a region,14 rather it was suggested that a reduced absolute risk of breast cancer for OCCR mutations contributed substantially to the effect described.15 All the above data pooled different but neighbouring BRCA1 or BRCA2 mutations and associated them with phenotypes. However, does a specific mutation in the BRCA1 or BRCA2 gene confer different phenotypes compared with other common mutations in the same gene? This is a question that remains unanswered especially pertaining to the recurrent BRCA1 exon 2, 11 and 13 mutations. The answer to this question could have important implications for screening, genetic counselling and prophylactic treatment of carriers. Therefore, there is currently a need to study the genotype-phenotype correlation among common mutations in BRCA1 and BRCA2 genes. Our paper addresses this need.
###end p 11
###begin title 12
METHODS
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 13
###begin p 14
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 505 513 <span type="species:ncbi:9606">Patients</span>
A total of 241 patients and their family members from Yorkshire and Humberside, UK, were chosen for BRCA1 and BRCA2 mutation testing. They belonged to 131 families classified as moderate to high risk of carrying a BRCA1 or BRCA2 mutation. High-risk individuals were members of families with four confirmed cases of breast and/or ovarian cancers, with breast cancer occurring under the age of 60 years or ovarian cancer at any age. Moderate-risk groups were defined as families with three cases of cancer. Patients were followed up for a mean of 81.87 months (range 0.33-343.6 months), and age at diagnosis and overall survival were recorded. Mutational and corresponding clinical data were available for 219 cases. For calculating age at diagnosis, the age and date at which cancer of the breast or ovary occurred was noted. For calculating overall survival, the date of death was recorded. In addition, for other subjects with a follow-up date, but no date of death, this was coded as censored. For one subject with no follow-up time recorded but dates of diagnosis and follow-up, the follow-up time was calculated from the dates.
###end p 14
###begin p 15
###xml 4 12 <span type="species:ncbi:9606">patients</span>
All patients and family members were counselled and signed a written informed consent before testing. The procedures followed were in accordance with the ethical standards implemented at the University of Kuwait and with the Declaration of Helsinki 1975, as revised in 1983.
###end p 15
###begin title 16
Mutation testing
###end title 16
###begin p 17
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
High-quality DNA was extracted from 5 ml EDTA-treated venous blood samples using a standard phenol-chloroform procedure. All DNA samples were screened for mutations at exon 2 (185delAG), exon 20 (5382insC) of BRCA1, and exon 11 (6147delT) of BRCA2, using amplification refractory mutation system PCR and duplication (Exon13dup6kb) of exon 13 by multiplex ligation-dependent probe amplification (P002; MRC-Holland, Amsterdam, The Netherlands) as instructed by the kit manufacturer (level 1 testing). DNA negative for these mutations was subjected to level 2 testing, which involved direct sequencing of all exon 11 in eight large PCR fragments. Negative samples were then subjected to level 3 testing that called for single-strand conformation polymorphism (SSCP) analysis and sequencing of all BRCA1 coding exons. Therefore, all samples that were negative for levels 1, 2 and SSCP were sequenced. In all reactions, positive (DNA with known mutations) and negative controls (wild-type DNA from normal individuals) were included. Primer sequences and reaction conditions are available online.16
###end p 17
###begin title 18
Statistical analysis
###end title 18
###begin p 19
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 511 519 <span type="species:ncbi:9606">Patients</span>
###xml 569 576 <span type="species:ncbi:9606">patient</span>
###xml 838 843 <span type="species:ncbi:9606">women</span>
Two outcomes were considered: age at diagnosis and time from diagnosis to death. As both of these are time to event data, Cox proportional hazards regression was used. Four groups of subjects were compared, defined by the exon where the mutation took place: exon 2, exon 11, exon 13 and all other exons. The hazard ratio for each group, exon 2, 11 and 13, compared to the other exons group were calculated, with an overall significance test of the effect of exon and confidence intervals for each hazard ratio. Patients were grouped into pedigrees, where more than one patient may belong to the same pedigree. Clustering within pedigrees was be adjusted for using robust standard errors by the method of Lin and Wei.17 For the time to death, we also controlled for age at diagnosis, to allow for potentially greater mortality among older women. All analyses were done using Stata 8 (Stata, College Station, Texas, USA).
###end p 19
###begin title 20
RESULTS
###end title 20
###begin title 21
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
BRCA1 and BRCA2 mutation frequencies in Yorkshire
###end title 21
###begin p 22
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 105 112 105 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t01">table 1</xref>
###xml 200 205 200 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="CPT-62-04-0350-f01">fig 1</xref>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
The present study included 131 families with moderate to high risk of carrying BRCA1 or BRCA2 mutations (table 1). An example pedigree from a family with exon 13 duplication is shown in supplementary fig 1. A total of 241 patients and their family members were screened for pathogenic germline mutations in the BRCA1 or BRCA2 gene.
###end p 22
###begin p 23
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
(A) Cumulative incidence for all cancer cases, by various BRCA1 exons. (B) Cumulative incidence of breast cancer cases, by various BRCA1 exons.
###end p 23
###begin title 24
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Breakdown of families with the most frequent BRCA1 mutations
###end title 24
###begin p 25
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 176 184 176 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t02">Tables 2</xref>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t03">3</xref>
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
One hundred and thirty-six (56%) individuals carried a mutated BRCA1 gene, 25 (10%) had a mutated BRCA2 gene, and 80 (33%) of the screened individuals carried wild-type genes. Tables 2 and 3 give the frequency and type of mutations in various exons of BRCA1 and BRCA2 genes respectively. The vast majority of mutations caused protein truncation. Moreover, we identified 14 novel mutations not previously reported in the BIC database.18
###end p 25
###begin title 26
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Frequencies and types of BRCA1 familial mutations
###end title 26
###begin p 27
*Novel mutations not reported in the Breast Cancer Information Core database.
###end p 27
###begin p 28
###xml 27 29 22 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
daggerReported in Pakistan.36
###end p 28
###begin p 29
double daggerNumber of families = 13.
###end p 29
###begin p 30
section signNumber of families = 12.
###end p 30
###begin p 31
paragraph signNumber of families = 11.
###end p 31
###begin title 32
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Frequencies and types of BRCA2 familial mutations
###end title 32
###begin p 33
*Novel mutations not reported in Breast Cancer Information Core database.
###end p 33
###begin p 34
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
For the BRCA1 gene, mutations in exon 11 were the most frequent (n = 58, or 42.3%) with 4184delTCAA accounting for the most common mutation within exon 11 (n = 29, or 50%). Exon 2 mutations were the second most frequent (n = 30, or 22%) with 185delAG being the most common mutation within exon 2 (n = 28, or 93.3%) followed by mutation of exon 13 (n = 20, or 14.6%) and exon 20 (n = 12, or 8.7%). For BRCA2 gene, mutations in exon 11 were the most frequent (n = 18, or 75%).
###end p 34
###begin title 35
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Association of BRCA1 and BRCA2 gene mutations with cancer occurrence and site
###end title 35
###begin p 36
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 268 275 268 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t04">table 4</xref>
###xml 583 590 583 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t05">Table 5</xref>
###xml 625 630 625 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 635 640 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 769 774 769 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 862 867 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1046 1047 1046 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 1099 1104 1099 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 1205 1212 1205 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t05">table 5</xref>
###xml 415 418 <span type="species:ncbi:9606">man</span>
###xml 461 466 <span type="species:ncbi:9606">woman</span>
###xml 523 528 <span type="species:ncbi:9606">woman</span>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
Matched mutations and clinical data were available for 219 individuals. The cohort included 40 (18%) males and 179 (82%) females. As expected, there was a significant association between the presence of BRCA1 or BRCA2 mutations and the occurrence of cancer; p<0.0001 (table 4). Of the affected cases, 63 had invasive breast cancer, 12 were diagnosed with ovarian cancer, 15 had both breast and ovarian cancers, one man developed colon and prostate cancers, one woman presented with ovarian and vaginal cancers, and another woman presented with breast and pancreatic adenocarcinomas. Table 5 lists cancer sites in relation to BRCA1 and BRCA2 mutations. Mutations in the BRCA1 gene accounted for the majority of breast and ovarian cancers in these families. In addition, BRCA1 mutations accounted for the majority of patients with both breast and ovarian cancers. BRCA2 mutations were more common in breast than ovarian cancer (the ratio of breast to ovarian cancers was 9:1). This is consistent with data from the Breast Cancer Linkage Consortium.7 Although the numbers were modest, mutations in the BRCA2 gene were significantly associated with the development of cancers outside the breast-ovarian axis (table 5).
###end p 36
###begin title 37
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients in relation to BRCA1 and BRCA2 mutations
###end title 37
###begin p 38
*Calculated using two-sided Fisher's exact test.
###end p 38
###begin p 39
daggerStudent t test was used to compare means.
###end p 39
###begin title 40
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Cancer sites in relation to BRCA1 and BRCA2 mutations
###end title 40
###begin p 41
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
*Site was unknown for five of 98 patients with cancer (three with exon 11, and two other exon mutations in the BRCA1 gene).
###end p 41
###begin p 42
daggerCalculated using two-sided Fisher's exact test.
###end p 42
###begin p 43
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
There was evidence that mutations in the 3' end of the BRCA1 gene (3' to exon 13) were less likely to be associated with ovarian cancer. For example, 90% of ovarian cancers were associated with mutations in the 5' end of the BRCA1 gene, while only 10% were linked to mutations in the 3' end. However, this trend was not statistically significant.
###end p 43
###begin title 44
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
BRCA1 exon 2 mutation penetrance
###end title 44
###begin p 45
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 174 181 174 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t06">table 6</xref>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 460 465 460 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 555 560 555 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
We noted that carriers of the exon 2 BRCA1 gene mutation had significantly lower cancer incidence compared with carriers of mutations of exons 11, 13 and 20. In this regard, table 6 shows that 15 (56%) of patients who carried the BRCA1 185delAG mutation were cancer free (p = 0.004). This suggested to us that either the 185delAG mutation is of low penetrance or, more likely, carriers of this mutation would develop cancer at an older age compared with other BRCA1 gene mutations. This observation led us to explore age-dependant expressivity of various BRCA1 exon mutations.
###end p 45
###begin title 46
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Relationship between various mutated BRCA1 exons and affliction with cancer
###end title 46
###begin p 47
*p = 0.004 using two-sided Fisher's exact test.
###end p 47
###begin title 48
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
BRCA1 mutations and age-related expressivity
###end title 48
###begin p 49
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t07">table 7</xref>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 666 667 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 910 917 908 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t07">table 7</xref>
###xml 1111 1116 1109 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1144 1149 1142 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="CPT-62-04-0350-f01">fig 1</xref>
###xml 51 56 <span type="species:ncbi:9606">women</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">Patients</span>
###xml 522 529 <span type="species:ncbi:9606">patient</span>
Of the 136 cases carrying a mutated BRCA1 gene, 79 women who developed breast and/or ovarian cancers were included in the analysis (table 7). Analysis of age-related expressivity pertaining to various BRCA2 gene mutations was not performed because of the small number of cases included in each mutation category. For BRCA1 gene, groups of patients were compared, defined by the exon where the mutations were located: exon 2, exon 11, exon 13, and all other exons. Patients were grouped into pedigrees, where more than one patient may belong to the same pedigree. Cox regression with clustering on pedigree showed that the exon was a highly significant predictor (chi2 19.75 with 3 degrees of freedom, p = 0.0002). Hence, there was a significant relationship between a specific exon mutation and age at diagnosis, mainly due to exon 2 having a much lower hazard or older age at diagnosis than the other groups (table 7). Clustering within pedigrees may have an adverse effect on p values and standard errors. The cumulative incidence for all cancer cases, or limited to breast cancers, and stratified by various BRCA1 exon mutations is shown in fig 1.
###end p 49
###begin title 50
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Cox regression analysis between specific BRCA1 exon mutation and age at diagnosis
###end title 50
###begin p 51
Hazard ratio of <1 indicates lower hazard than the other groups and hence older ages at diagnosis.
###end p 51
###begin p 52
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 323 324 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 381 388 379 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t08">table 8</xref>
###xml 492 499 490 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t09">table 9</xref>
###xml 615 620 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 422 427 <span type="species:ncbi:9606">woman</span>
###xml 541 546 <span type="species:ncbi:9606">women</span>
We then asked if the relationship between various BRCA1 exon mutations and age at diagnosis is different for different cancer sites. For this, we carried out Cox regression analysis with exon and tumour site as factors. The estimates of the hazard ratios were very little changed by including both exon and tumour site (chi2 statistic 23.09 with 5 degrees of freedom, p = 0.0003) (table 8). Also, limiting the analysis to woman with breast cancer only, the hazard ratios changed very little (table 9). This is not surprising, as most of the women belonged to this group. Hence there is strong evidence that various BRCA1 exon mutations have an effect on age-dependent expressivity that was not explained by cancer site.
###end p 52
###begin title 53
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Cox regression analysis including specific BRCA1 exon mutation and cancer sites as covariates
###end title 53
###begin title 54
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Cox regression analysis between specific BRCA1 exon mutation and age at diagnosis limited to breast cancer only
###end title 54
###begin title 55
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Specific BRCA1 mutations and age-related expressivity
###end title 55
###begin p 56
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 417 424 417 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="CPT-62-04-0350-t01">table 1</xref>
###xml 427 435 427 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="CPT-62-04-0350-f02">Figure 2</xref>
###xml 735 740 735 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Exon 11 is the largest exon in the BRCA1 gene and harbours a number of different mutations in different patients; these mutations were grouped in this study under the term "exon 11 mutations". To minimise any confounding error emanating from such grouping, we limited the analysis to three specific and most common mutations in exons 2, 11 and 13, namely, 185delAG, 4184delTCAA and exon 13 duplication, respectively (table 1). Figure 2 shows that median age of affliction with breast cancer was 55 years for 185delAG in exon 2 (hazard ratio (HR) 0.23, 95% CI 0.095 to 0.55, p = 0.001) and 47 years for the 4184delTCAA mutation in exon 11 (HR 0.49, 95% CI 0.225 to 1.08, p = 0.076) compared with 41 years for exon 13 duplication of the BRCA1 gene. It is worthy of note that the inclusion of a large pedigree (2802) carrying the 185delAG mutation could have confounding influence on the major conclusion emanating from our study. However, exclusion of this pedigree from the analysis did not have any impact on our data stating that exon 2 mutation 185delAG has lower penetrance that is age dependent (HR 0.22, 95% CI 0.09 to 0.56, p = 0.002).
###end p 56
###begin p 57
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Kaplan-Meier plots of cumulative survival and age at diagnosis with breast cancer in relation to specific BRCA1 exon mutations. The p value indicates log-rank test.
###end p 57
###begin title 58
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
BRCA1 mutations and survival analysis
###end title 58
###begin p 59
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 198 199 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 288 293 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 566 571 564 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="CPT-62-04-0350-f03">fig 3</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Overall survival data were available from 61 patients. The Cox regression with clustering on pedigree, including BRCA1 exon mutation and age at diagnosis, gave no overall significant prediction: chi2 = 3.72 with 4 degrees of freedom, p = 0.4. Thus there was no evidence that any specific BRCA1 exon mutation can predict overall survival from date of diagnosis. However, as expected, risk of death increased slightly with age at diagnosis, though this was not significant. The raised HRs suggest that this analysis would be worth repeating with a much larger sample (fig 3).
###end p 59
###begin p 60
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier plot of overall survival of patients in relation to BRCA1 exon mutations (the table depicts the hazard ratios).
###end p 60
###begin title 61
DISCUSSION
###end title 61
###begin p 62
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 464 469 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 691 696 691 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 700 705 700 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 814 819 814 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 823 828 823 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1189 1191 1189 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
The aim of this study was to elaborate on the expressivity of various BRCA1 gene mutations in relation to penetrance and age of cancer diagnosis. To this end, a total of 241 patients and their family members (of whom 219 had relevant clinical data) were screened for pathogenic germline mutations in BRCA1 or BRCA2 genes and the results were associated with clinical parameters. We opted for a family-based study to maximise the number of individuals with mutated BRCA1 or BRCA2 genes. Although this approach suffers from bias compared with a population-based study, it was necessary as the latter approach requires a very large cohort to attain a similar number of individuals with mutated BRCA1 or BRCA2 genes. Therefore, >4000 individuals in a population are required to be tested to yield 141 individuals with BRCA1 or BRCA2 mutations.19 The extent of bias is difficult to infer. For example, it is generally accepted that family-based studies usually overestimate the lifetime risks of cancer because the presence of additional genetic factors could elevate risks for the relatives. Nevertheless, the use of appropriate statistical methods could alleviate some aspects of this bias.2021
###end p 62
###begin p 63
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 497 501 497 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA</italic>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 625 630 625 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 782 787 782 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 792 797 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 895 900 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 922 927 922 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 1129 1134 1129 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1502 1504 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 1588 1593 1588 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1895 1900 1895 1900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1926 1928 1926 1928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1956 1961 1956 1961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 2054 2059 2054 2059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 2270 2272 2270 2272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 1027 1032 <span type="species:ncbi:9606">human</span>
In this study we have exhaustively searched for mutations in the BRCA1 and BRCA2 genes using a level approach that involved starting from screening for known founder mutations up to sequencing all exons in addition to various exon rearrangements. This methodology would increase the sensitivity of detecting BRCA1 and BRCA2 gene mutations, and this was reflected in our high pickup mutation rate accounting for 67% of individuals recruited in this study. A total of 56% of individuals harboured a BRCA1 mutated gene; this figure is similar to the one previously estimated for the UK population.9 Similarly, the proportion of BRCA2 mutation-bearing individuals in this study is within the range previously published for the UK.22 It is well accepted that mutation frequencies of the BRCA1 and BRCA2 genes in high-risk families vary widely among different populations, being highest in Russia for BRCA123 and in Iceland for BRCA2.24 This could be due to ascertainment or methodological bias, or more likely it is a reflection of human migration and establishment of founders. In our UK East Midlands series, three mutations in the BRCA1 gene were recurrent, namely 4184delTCAA, accounting for the most common mutation within exon 11 (found in 16 families), 185delAG, being the most frequent mutation within exon 2 (found in 11 families), and duplication of exon 13 (found in 12 families). The BIC database lists 185delAG, 4184delTCAA and exon 13 duplication among the 20 most frequent recurrent mutations18; these are consistent with our data. Also, our data are in line with the fact that BRCA1 exon 13 duplication has been reported as a founder mutation in Britain, and English-speaking counties with historical links to Britain. In that regard, 50% of the exon 13 duplication mutations were demonstrated in Britain, mainly Yorkshire, suggesting a northern British origin for this mutation (the BRCA1 exon 13 screening group).25 Interestingly, none of the BRCA2 mutations were repeated in more than two families, probably indicating the presence of many BRCA2 founders (or de novo mutations). Although we did not haplotype families carrying the 185delAG mutation, previous haplotypes from Yorkshire indicated independent origins of the mutation from the Jewish founders.26
###end p 63
###begin p 64
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 515 520 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
Our data are consistent with the fact that mutations in BRCA1 and BRCA2 are associated with increased risk of cancer.327 Both BRCA1 and BRCA2 mutations were significantly associated with development of breast cancer. On the other hand, BRCA2, but not the BRCA1 gene, was significantly linked to the development of cancer outside the breast-ovarian axis. This is in agreement with data showing that mutations in the BRCA1 gene are rarely linked to cancer at sites other than breast and ovary, while mutations in the BRCA2 gene are.2829
###end p 64
###begin p 65
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
Regarding the controversial issue linking mutations of the 3' end of the BRCA1 to lower incidence of ovarian cancer, our data show that ovarian cancer is indeed lower when mutations inflict the 3' end of the BRCA1 gene. However, the trend was insignificant and a larger study is needed to resolve this issue.9
###end p 65
###begin p 66
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 666 671 666 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 770 775 770 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 990 995 990 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1315 1317 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 1834 1839 1834 1839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 1844 1849 1844 1849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 2072 2077 2072 2077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 2096 2098 2096 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 2098 2100 2098 2100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 2258 2263 2258 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 2332 2337 2332 2337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2460 2462 2460 2462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 2690 2695 2690 2695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 2749 2754 2749 2754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 2851 2853 2851 2853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 2926 2931 2926 2931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 3108 3110 3108 3110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 3534 3539 3534 3539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 3814 3819 3814 3819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 4062 4067 4062 4067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 691 696 <span type="species:ncbi:9606">woman</span>
###xml 787 792 <span type="species:ncbi:9606">woman</span>
###xml 1202 1207 <span type="species:ncbi:9606">women</span>
###xml 1282 1287 <span type="species:ncbi:9606">woman</span>
###xml 1915 1920 <span type="species:ncbi:9606">women</span>
###xml 3800 3808 <span type="species:ncbi:9606">patients</span>
Perhaps the most intriguing finding of this study was the notion that different mutations in the BRCA1 gene have significantly different effect on age-dependent expressivity. To the best of our knowledge this is the first time that different age-dependent expressivity, independent of cancer site, has been reported for three of the most common BRCA1 mutations, namely 185delAG, 4184delTCAA and exon 13 duplication. For the exon 13 duplication mutation, we reported a mean age of cancer diagnosis at 41.4 years (95% CI 36.99 to 45.78) from 12 independent families. Data on the age-dependent penetrance/expressivity for exon 13 duplication are scarce. However, Unger et al reported a Belgian woman with this mutation who developed cancer at age 34 years.30 Moreover, Yap et al reported a woman diagnosed with bilateral breast cancer at ages 32 and 41 years and her sister, carrying the same exon 13 duplication mutation, was diagnosed with ovarian cancer at age 43 years.31 For the 185delAG BRCA1 mutation, although the frequency of the mutation was, as expected, among the highest, we report significantly lower cancer rates in carriers of this mutation. This has been observed before in Iraqi/Iranian women, who have a significantly lower penetrance compared with Ashkenazi Jewish woman carrying the same mutation.32 Therefore, it remains to be elucidated whether this difference in penetrance could be due to other genetic variation such as different haplotypes, environmental or cultural influences. More importantly, we report here that the mean age of cancer diagnosis from 12 separate families carrying the 185delAG mutation was 55 years (95% CI 49.3 to 60.7), which is a significantly older age of cancer diagnosis compared with exon 13 duplication mutation. In a recent report, using a meta-analysis of pedigree data from 498 BRCA1 and BRCA2 mutation carriers identified through population-based studies of women with breast and ovarian cancer, the authors have shown, albeit not significantly, that cancer risk by age 50 years is lower for 185delAG than 5382insC BRCA1 mutation carriers.1933 Our data are consistent with this. The question of why the 185delAG mutation has a lower cancer-related expressivity that is age dependent compared to other BRCA1 mutations remains to be elucidated. Recently, however, Perrin-Vidoz et al, reported that transcripts bearing the 185delAG mutation are not subjected to degradation by nonsense-mediated mRNA decay.34 This important observation leads us to hypothesise that even in the presence of the 185delAG mutation there could still be some truncated, but functional, BRCA1 protein delaying the onset of cancer. In support of this, Buisson et al have demonstrated translational re-initiation in the BRCA1 minigenes at position 128 in the presence of a premature termination codon at position 36 or 39.35 However, using western blotting and immunoprecipitation, we and Buisson et al were unable to detect N-terminally or C-terminally truncated BRCA1 proteins from lymphocytes of carriers, probably indicating an unstable nature of the truncated BRCA1 protein.35 Nevertheless, the truncated BRCA1 protein could still be functional in a microenvironment or at concentrations beyond the detection limit of current technologies. This hypothesis remains to be proven. Obviously, the role of other genetic background or haplotypes and environmental influences on age-dependent expressivity cannot be underestimated. For example, we do not know whether carriers of exon 13 duplication in the BRCA1 gene have other genetic aberrations that could influence expressivity. Regardless of the mechanism, our findings have important ramifications regarding the design of future studies for the estimation of cancer risks and more specifically on the counselling of patients with BRCA1 mutations, in that the mutation type should be included in risk calculations. Moreover, the time of screening and prophylactic treatments of carriers should be adjusted to take into account the different age-dependent expressivity of various BRCA1 gene mutations.
###end p 66
###begin title 67
Take-home messages
###end title 67
###begin p 68
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
The 185delAG mutation of the BRCA1 gene is a low penetrance mutation that is age dependent.
###end p 68
###begin p 69
Carriers of the exon 13 duplication mutation are at risk of developing cancer at younger age.
###end p 69
###begin p 70
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
We report 14 novel mutations in the BRCA1 and BRCA2 genes in the Yorkshire/Humberside population.
###end p 70
###begin p 71
Clinical geneticists should take the mutation site and type into consideration in risk calculations.
###end p 71
###begin p 72
We dedicate this work in memory of Elizabeth Redmond. We would like to thank the staff of DNA laboratory at St James's Hospital Leeds for their help and support with the data. Part of this work was supported by grant number (2006130207) given to Fahd Al-Mulla by the Kuwait Foundation for the Advancement of Sciences.
###end p 72
###begin title 73
REFERENCES
###end title 73
###begin article-title 74
Global cancer statistics, 2002.
###end article-title 74
###begin article-title 75
Modifiers of risk of hereditary breast and ovarian cancer.
###end article-title 75
###begin article-title 76
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
###end article-title 76
###begin article-title 77
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.
###end article-title 77
###begin article-title 78
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
###end article-title 78
###begin article-title 79
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
###end article-title 79
###begin article-title 80
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
###end article-title 80
###begin article-title 81
On the use of familial aggregation in population-based case probands for calculating penetrance.
###end article-title 81
###begin article-title 82
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
###end article-title 82
###begin article-title 83
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 19 24 <span type="species:ncbi:9606">women</span>
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
###end article-title 83
###begin article-title 84
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
###end article-title 84
###begin article-title 85
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families.
###end article-title 85
###begin article-title 86
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
###end article-title 86
###begin article-title 87
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.
###end article-title 87
###begin article-title 88
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.
###end article-title 88
###begin article-title 89
The robust inference for the Cox proportional hazards model.
###end article-title 89
###begin article-title 90
Breast Cancer Information Core database.
###end article-title 90
###begin article-title 91
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
###end article-title 91
###begin article-title 92
A marginal likelihood approach for estimating penetrance from kin-cohort designs.
###end article-title 92
###begin article-title 93
Bias and efficiency in family-based gene-characterization studies: conditional, prospective, retrospective, and joint likelihoods.
###end article-title 93
###begin article-title 94
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Population genetics of BRCA1 and BRCA2.
###end article-title 94
###begin article-title 95
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia.
###end article-title 95
###begin article-title 96
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.
###end article-title 96
###begin article-title 97
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations.
###end article-title 97
###begin article-title 98
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families.
###end article-title 98
###begin article-title 99
Linkage of early-onset familial breast cancer to chromosome 17q21.
###end article-title 99
###begin article-title 100
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families.
###end article-title 100
###begin article-title 101
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Cancer incidence in BRCA1 mutation carriers.
###end article-title 101
###begin article-title 102
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing.
###end article-title 102
###begin article-title 103
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Detection of a novel Alu-mediated BRCA1 exon 13 duplication in Chinese breast cancer patients and implications for genetic testing.
###end article-title 103
###begin article-title 104
Cancer incidence in Jewish migrants to Israel, 1961-1981.
###end article-title 104
###begin article-title 105
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
###end article-title 105
###begin article-title 106
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons.
###end article-title 106
###begin article-title 107
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon.
###end article-title 107
###begin article-title 108
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA2</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
###end article-title 108
###begin p 109
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests:</bold>
Competing interests: None.
###end p 109

